Experts in breast cancer discuss precision medicine in treatment of patients with metastatic triple negative breast cancer.
Data from the following clinical trials are discussed:
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (Cortes J et al. 2020 ASCO annual meeting. Abstract 1000.)
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response pathway genes (Olaparib Expanded). (Tung NM et al. 2020 ASCO annual meeting. Abstract 1002.)
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer and/or germline BRCA-associated breast cancer (SWOG S1416). (Sharma P et al. 2020 ASCO annual meeting. Abstract 1001.)
Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial. (Ayoub J et al. 2020 ESMO Breast Cancer annual meeting. Abstract 140O.)
Final results of the double-blind placebo-controlled randomized phase II LOTUS trial of first-line ipatasertib + paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. (Dent R et al. 2020 ESMO Breast Cancer annual meeting. Abstract 139O.)